Bill > SB77

This bill establishes a new fund, the "ibogaine research and intellectual property fund," administered by the Department of Agriculture, to facilitate a public-private partnership with a drug developer. This partnership aims to conduct clinical trials for ibogaine, a compound derived from the Tabernanthe iboga plant and its derivatives, to treat opioid use disorder, co-occurring substance use disorder, or other neurological or mental health conditions where it shows effectiveness. Before contracting, the drug developer must provide detailed plans for FDA approval, trial design, participant recruitment, and after-care, along with financial disclosures and proof of existing agreements with other states. The department will negotiate contracts requiring the drug developer to match the Commonwealth's investment, use in-state resources for trials, report progress, and ensure accessible treatment for residents, including those uninsured or low-income, after potential FDA approval. The bill also mandates that the drug developer share a proportional amount of proceeds from any intellectual property generated by the research back into the fund. To support this initiative, $21 million will be appropriated from the opioid abatement trust fund to the ibogaine research and intellectual property fund in each of the 2026-2027 and 2027-2028 fiscal years, with the bill taking effect immediately due to an declared emergency.

https://apps.legislature.ky.gov/record/26RS/sb77.html